Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia

Real-World Outcomes of First-Line Pembrolizumab Monotherapy in Metastatic NSCLC with High PD-L1 Expression (TPS ≥ 50%): A Multicenter Study from Serbia

<b>Background:</b> Pembrolizumab monotherapy is the standard first-line treatment for metastatic non-small cell lung cancer (NSCLC) patients whose tumors express a PD-L1 tumor proportion score (TPS) of ≥50%. However, real-world data regarding its effectiveness outside of clinical trials,...

Full description

Saved in:
Bibliographic Details
Main Authors: Filip Marković, Mihailo Stjepanović, Milan Rančić, Marina Cekić, Milica Kontić
Format: Article
Language:English
Published: MDPI AG 2025-05-01
Series:Biomedicines
Subjects:
first-line
high PD-L1 expression
immune check-point inhibitors
non-small cell lung cancer
pembrolizumab
predictive factors
Online Access:https://www.mdpi.com/2227-9059/13/5/1175
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://www.mdpi.com/2227-9059/13/5/1175

Similar Items